In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
about
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.Neoplasms derived from plasmacytoid dendritic cells.Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.Report on Three Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
P2860
Q30249813-270998B6-EC6F-43C8-9405-47ED1D73C442Q30827633-14B8172C-87F8-465F-9FBB-B5FA734177A1Q38629837-464C1526-5D23-437A-88BA-5FE56A5B5CE1Q38689894-EC83F44B-808C-4DF0-9B5D-4647D2488073Q38737657-86464113-FD2F-41DC-B392-47234C33E5E4Q38739920-4BB434A6-FB06-407A-A974-0F457E117C09Q45871879-2EC0929C-FC1C-4B73-A4EB-3E64D9EAB2FFQ48158203-387E4D09-5FF8-4D79-8B76-274AA4E88FB3Q50581082-C8785F1B-C667-4F9C-871D-84A40FBFD8C0Q51016220-13CF478B-1FD4-4430-BD59-160F7EFD984AQ52648918-EF2BDB82-3F22-41A0-86B1-4DE01FDC3FB8Q58800035-A726DCD4-6B3D-410D-996D-53C8A451C618
P2860
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@ast
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@en
type
label
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@ast
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@en
prefLabel
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@ast
In vivo and in vitro sensitivi ...... eptor targeted biologic agent.
@en
P2093
P2860
P50
P1433
P1476
In vivo and in vitro sensitivi ...... ceptor targeted biologic agent
@en
P2093
Agathe Debliquis
Anne Roggy
Arthur E Frankel
Bernard Royer
Blandine Benet
Christopher Brooks
Daniel Lusina
Eric Deconinck
Eric K Rowinsky
Estelle Seilles
P2860
P304
P356
10.3324/HAEMATOL.2014.111740
P577
2014-11-07T00:00:00Z